Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study

@inproceedings{Kavanaugh2015ImprovementsIP,
  title={Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study},
  author={Arthur Kavanaugh and Dd Gladman and D{\'e}sir{\'e}e M van der Heijde and Oana Purcaru and Philip J. Mease},
  booktitle={Annals of the rheumatic diseases},
  year={2015}
}
OBJECTIVES To evaluate the effect of certolizumab pegol (CZP) on productivity outside and within the home, and on participation in family, social and leisure activities in adult patients with psoriatic arthritis (PsA). METHODS RAPID-PsA (NCT01087788) is a phase 3, double-blind, placebo-controlled trial. 409 patients with active PsA were randomised 1:1:1 to placebo, CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS) assessed… CONTINUE READING
1
Twitter Mention

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Psoriatic Arthritis: a Critical Review

  • Clinical Reviews in Allergy & Immunology
  • 2012